Skip to content
‹ Back to IndustriesHealthcare

The University of Kansas Announces Grant Funding for Knee Imaging Biomarkers Acquired from Weight Bearing CT

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT imaging and the critical need for more sensitive and affordable imaging biomarkers.

Osteoarthritis (OA) is the most prevalent form of arthritis, and the knee is the most commonly affected weight-bearing joint. The high cost of clinical trials creates a barrier for effective treatment development. Therefore, introduction of more specific and sensitive biomarkers could help to advance therapeutic development by reducing the time and sample sizes required for clinical trials.

Proposed Outcomes

There is an urgent need for imaging biomarkers that allow for identification of the best time in which patients will respond to treatment, and a means to analyze the efficiency of interventions. Early studies demonstrated the diagnostic value of bilateral weight-bearing CT in identifying knee OA symptoms accurately, as well as the feasibility to detect meniscal tears not detected by non-weight bearing MRI.

The grant from NIAMS will fund a study to validate the proposed imaging biomarkers and begin the qualification process for more responsive OA imaging biomarkers acquired using low-dose, bilateral standing CT imaging. Substantial advantages are offered over traditional radiographic biomarkers, including increased responsiveness to temporal changes in the joints, and a better reflection of the symptoms and severity of the disease. Additionally, this research will determine the prognostic validity of standing CT findings for detecting progression and worsening pain in people who currently suffer from or are at risk for knee OA.

Long-Term Impact

With the support of NIAMS, this research holds promise to detect joint damage earlier, and accelerate the pace of scientific discovery and clinical trials. The continuing impact will be evident through a shift in knee joint imaging with an improved biomarkers for monitoring knee OA disease features. If the additional meniscal extrusions detected on bilateral standing CT are clinically relevant, then standing CT could improve identification of the most appropriate patients for clinical trials – those at risk of rapid OA progression. Successful completion will provide improved biomarkers that will help those who suffer from knee OA through making clinical trials more affordable and accelerating therapeutic improvement.

For more information on visualizing cartilage and menisci in the knee using standing CT arthrogram versus MRI, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why MVP wants to push fresher care-gap data into EMRs

Why MVP wants to push fresher care-gap data into EMRs

MVP Health Care, a nonprofit insurer in New York and Vermont, built Arcadia-based provider dashboards that combine ADT alerts, care gaps, utilization and pharmacy data. Timing drives the design. Its next step, delivering care gaps inside provider EMRs, should move fastest with practices that already exchange data through Arcadia.

  • 01For a quality measure on a seven-day clock, a payer report that runs a few months behind arrives after the deadline it was meant to help with.
  • 02The quickest EMR integrations for a regional payer are likely with practices already sharing data on the same platform through Medicare ACOs or other payers. Practices new to that kind of exchange need trust built in both directions first.
  • 03A useful test for any payer’s provider analytics: does a service completed last week drop off the care-gap list, or does the practice still call the patient again?

Nov 13, 2026

Humana's $2.8B BlackRock deal lets it buy back CenterWell clinics starting in 2028

Humana's $2.8B BlackRock deal lets it buy back CenterWell clinics starting in 2028

BlackRock's $2.8 billion buys majority ownership of a joint venture holding about 150 CenterWell clinics, replacing WCAS as Humana's outside investor. CenterWell keeps a minority stake and keeps running the clinics. The terms set a timeline: two years of expected growth spending, an option for Humana to buy clinics back from 2028, and a BlackRock right to start a sale of any clinics still in the venture at the end of 2033, with CenterWell getting the first offer. The deal is expected to close in the fourth quarter, subject to regulatory approvals.

  • 01BlackRock's $2.8 billion buys majority ownership of about 150 CenterWell clinics, while Humana keeps day-to-day management and an option to repurchase clinics starting in 2028.
  • 02The 2028 buyback and 2033 sale terms apply to the roughly 150 clinics in the new joint venture. CenterWell Senior Primary Care runs 250 clinics in total.
  • 03The deal’s lower-cost-of-capital claim will be tested after closing—first by how the venture deploys new capital over the next two years to support clinics, open locations and pursue acquisitions, and then by Humana’s 2028 decision on whether to start buying clinics back.

Nov 12, 2026

Healthcare AI should give doctors attention back, not shorter visits

Healthcare AI should give doctors attention back, not shorter visits

Healthcare organizations should deploy AI to give clinicians back attention and capacity for better decisions, not simply shorten visits. Landry argues AI should fit into existing workflows with insights appearing at the right time, and that organizations should set clear governance and automation boundaries before deployment and measure what changes for patients, clinicians and the organization.

  • 01AI success in healthcare should expand clinician capacity for thoughtful care, not optimize for visit speed; a three-minute appointment is not patient-centered innovation.
  • 02Design AI into workflows clinicians already use with insights appearing at the right moment, making adoption a workflow problem rather than a training problem.
  • 03Set automation boundaries before deploying AI, specifying what it may do alone, what it recommends for clinician decision-making, and what requires explicit human control and accountability.

Nov 11, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512